A recent study (DY Graham, A Tansel. Clin Gastroenterol Hepatol 2018; 16: 800-808) analyzed 56 randomized trials to determine relative potency of proton pump inhibitors (PPIs) based on time in which intragastric pH was 4 or less (pH4time).
Key findings:
- Pantoprazole 20 mg was equivalent to 4.5 mg of omeprazole
- Lansoprazole 15 mg was equivalent to 13.5 mg of omeprazole
- Esomeprazole 20 mg was equivalent to 32 mg of omeprazole
- Rabeprazole 20 mg was equivalent to 36 mg of omeprazole
The authors note that peak effectiveness for PPIs was at ‘approximately 70 mg of omeprazole equivalents’. In addition, they state that twice a day dosing was more effective than increasing once a day dosing; however, three times a day dosing was not more effective than twice a day. “Dexlansoprazole, a quasi-twice-a-day formulation produced similar acid suppression to the lowest twice-daily PPI regimen and 20 mg vonoprazan once daily provided similar efficacy aas high-dose twice-daily PPI.” The authors also compare costs; generics of pantoprazole, omeprazole, and esomeprazole cost as little as $0.02-0.04 per omeprazole equivalent. Thus, 20 mg of omeprazole would be as little as 40 cents.
My take: Using the lowest effective dose of a PPI is recommended. In patients needing higher dosing or with suboptimal response to acid suppression, this data can be very helpful.
Pingback: Most Popular Posts of 2019 | gutsandgrowth
Pingback: Deconstructing PPI-Associated Risks with Nearly 8 Billion Data Points and More on COVID-19 GI Symptoms (Video) | gutsandgrowth
Pingback: Reducing Inappropriate Proton Pump Inhibitor Usage & U.S. Children with COVID-19 | gutsandgrowth
Pingback: Job Security Study: Lots of People Have Reflux Symptoms & COVID-19 Due To Singing | gutsandgrowth
Pingback: Most Popular 2020 Posts | gutsandgrowth
Pingback: Most Popular Posts of 2021 | gutsandgrowth